Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today ...

In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

Viridian Therapeutics' shares rose after the company said its treatment for thyroid eye disease met its primary endpoint in a recent trial. The stock gained 58% to $22.30 in premarket trading Tuesday.

Viridian Therapeutics, Inc. VRDN shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 ...

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.1% and a 54.0% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys ...

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients, sending its ​shares up nearly 50% before the bell. The drug ...

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

Commodore Capital exited 3,200,000 shares of Viridian Therapeutics. As a result, the net position value decreased by $69.06 million due to the complete share sale. The position was previously 3.4% of ...

Viridian Therapeutics (NASDAQ:VRDN) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated ...